Cerus Corporation (NASDAQ:CERS) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET

Company Participants

Jessica Hanover - Vice President-Corporate Affairs

Obi Greenman - president and Chief Executive Officer

Vivek Jayaraman - Chief Operating Officer

Kevin Green - Chief Financial Officer

Laurence Corash - Chief Scientific Officer

Conference Call Participants

Jacob Johnson - Stephens

Mathew Blackman - Stifel

Joshua Jennings - TD Cohen

Operator

Good day, ladies and gentlemen. Thank you for standing by and welcome to the Cerus Corporation’s Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Jessica Hanover, Cerus' Vice President of Corporate Affairs. Dr. Hanover, you may begin.

Jessica Hanover

Thank you and good afternoon. I'd like to thank everyone for joining us today. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the Investor Relations website at ir.cerus.com.

With me on the call are Obi Greenman, Cerus' president and Chief Executive Officer; Vivek Jayaraman, Cerus's Chief Operating Officer; Kevin Green, Cerus' Chief Financial Officer; Dr. Nina Mufti, Cerus' Vice President of Development and Red blood Cell Program Leader; Dr. Richard Benjamin, Cerus' Chief Medical Officer, dr. Laurence Corash, Cerus' Chief Scientific Officer and Carol Moore, Cerus' senior Vice President of Regulatory Affairs and Quality.

Cerus issued a press release today announcing our financial results for the second quarter ended June 30th, 2023, and describing the company's recent business highlights. You can access a copy of this announcement on the company website at www.cerus.com. I'd like to remind you that some of the statements we will make on this call related to future events and performance rather than historical facts and are forward-looking statements. Examples of forward-looking statements include those related to our future financial and operating results, including our updated 2023 product revenue guidance, expected operating expense savings, our adjusted EBITDA goal and future operating expenses, as well as our commercial development efforts, expected future growth and our growth strategy, future product sales, potential product launches, ongoing and future clinical trials ongoing and future product development, and our regulatory plans and initiatives and related expectations, including the timing of these events and activities.

These forward-looking statements involve risks and uncertainties that could cause actual events, performance and results to differ materially. They are identified and described in today's press release and under Risk Factors in our form 10-Q for the quarter ended June 30th, 2023, which we will file shortly.